Abstract: Recent advances in our understanding of the mechanisms through which T cells are activated have led to new therapeutic approaches in the treatment of immunological disorders. An emerging target for selective immune intervention has been the manipulation of T cell costimulatory pathways. Impressive results in animal models have shown that the tumor-necrosis-factor receptor (TNFR) family member, OX40 (CD134), and its binding partner OX40L, are key costimulatory molecules involved in the regulation of many T cell mediated immune disorders. In this review we will highlight these new findings with a particular emphasis on their potential implications for immunotherapy of human disease.
INTRODUCTION
T lymphocytes, as part of the adaptive immune system, play a critical role in protection against exposure to infectious agents such as viruses, bacteria, and helminth parasites. They can be separated into two subpopulations based on their differential expression of the cell surface markers, CD4 and CD8. Antigen specific CD4+ T cells help phagocytic cells, such as macrophages and dendritic cells to destroy vesicular and intracellular pathogens. Similarly, their interaction with B lymphocytes promotes antibody production. CD4+ T cells also play an important role in the induction of inflammatory responses and the generation of CD8+ T cell immunity. Effective priming of CD8+ T cells leads to their maturation to cytotoxic T lymphocytes (CTLs), with a unique capacity to kill virus-infected cells and tumor cells.
Despite the effectiveness of the immune system in protecting against many viral and bacterial pathogens, there are still numerous pathogens for which T cell responses are not easily generated or maintained, such as herpes viruses, human immunodeficiency virus (HIV), and certain bacterial infections. Moreover, excessive T helper type 1 (Th1) cell mediated immune responses can also be generated against self-antigens and can contribute to pathologies found in autoimmune disease, whereas aberrant Th2 responses have been implicated in atopy and allergic asthma.
An emerging target for selective immune intervention to treat cancer, autoimmunity, asthma, and many immunemediated inflammatory disorders has been the manipulation of membrane bound receptors, termed costimulatory molecules, which are able to control the activities of T cells. In particular, results in basic and disease-related systems have now implicated the tumor-necrosis-factor receptor (TNFR) family member, OX40 (CD134), and its binding *Address correspondence to this author at the La Jolla Institute for Allergy and Immunology, Division of Molecular Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA; Tel: (858) 678-4510; Fax: (858) 558-3525; E-mail: mick@liai.org partner OX40L, as key co-stimulatory molecules involved in proliferation, differentiation, survival, effector function, and memory development of CD4 and CD8 T cells [1] . Reagents that interfere with the binding of OX40 to OX40L have now been shown to suppress T cell responses and pathogenic symptoms in a number of immune based diseases. Conversely, reagents that augment OX40 signals have shown therapeutic efficacy in models of cancer and infectious disease.
T CELL COSTIMULATION AND IMMUNO-THERAPY
Considerable evidence gathered over the past twenty years has established that in addition to recognition of peptide bound to MHC by the T cell receptor (TCR), optimal proliferation and acquisition of effector function by naïve T cells only ensues when additional costimulatory signals are provided by antigen presenting cells (APC). The Ig superfamily member CD28, a receptor for both B7-1 (CD80) and B7-2 (CD86), is considered to be the primary costimulatory receptor that controls initial division, and survival signals to T cells and also controls their ability to secrete effector proteins such as cytokines [2] . Accordingly, TCR engagement in the absence of CD28 signals leads to aborted activation and death of T cells or to a prolonged state of anergy or clonal unresponsiveness. In the past decade the therapeutic applications of targeting this pathway have been vigorously investigated, with intervention strategies proposed for cancer, transplantation, and many autoimmune, allergic, and inflammatory disorders. However, it is becoming increasingly evident that although CD28 costimulation is essential for initial T cell priming, many activities of an effector or memory T cells, are CD28-independent. This implies that targeting this pathway alone may be of limited use in established disease. Indeed, more recent data in experimental disease models have shown that targeting the CD28/B7 pathway is effective in inhibiting or enhancing T cell mediated immune responses only when administered at the time of initial T cell activation; delaying these treatments has in many situations been ineffective and in some cases even resulted in exacerbation of the disease. For this reason considerable attention has focused on lateacting inducible costimulatory molecules of the TNFR superfamily as potential new avenues to treat established disease. In this regard, OX40 has emerged as a costimulatory pathway with compelling therapeutic promise.
EXPRESSION CHARACTERISTICS OF OX40 AND OX40L
OX40 was first identified in 1987 as a 50 kDa glycoprotein expressed on activated CD4 T cells from the rat [3] . OX40 has since been characterized in mouse and human (Table 1) , where its expression is also largely restricted to activated T cells. Although OX40 has been reported to be expressed predominantely on CD4 T cells [4, 5] , CD8 T cells can also express OX40 under strong inflammatory conditions [6] [7] [8] [9] . Unlike CD28, OX40 is not constitutively expressed on naïve T cells but is induced hours to days after engagement of the TCR [5, 7, 10, 11] . Peak levels are generally seen between 2 and 5 days after T cell activation and then OX40 is downregulated several days later, implying a delayed mode of action in primary immune responses. In contrast, antigen-experienced memory/effector T cells can rapidly re-express OX40 within 4 hours of reactivation, suggesting an earlier role in immune responses of memory T cells when antigens are re-encountered [11, 12] .
The ligand for OX40 (OX40L) was originally identified on transformed T cell lines as human gp34 whose expression was markedly induced by the tax gene of human T cell leukemia virus (HTLV)-1 [13, 14] . However, expression on non-transformed T cells appears to be rare and may depend on as yet undefined inflammatory conditions, or restricted to specialized sites such as the gut [15, 16] . The most important cells expressing OX40L are likely to be professional APCs, such as activated B cells [17, 18] , mature myeloid-and lymphoid-like dendritic cells (DCs) [19] [20] [21] and plasmacytoid DCs [22] . However NK cells [23] , mast cells [24] , airway smooth muscle cells [25, 26] , and vascular endothelial cells [27] [28] [29] , have also been reported to express OX40L in some instances ( Table 1) . Depending on the cell type, maturation stage and inflammatory milieu, reverse signaling through OX40L has been associated with a wide range of biological effects, including proliferation, differentiation, survival, migration, and cytokine/chemokine production [17, 19, [30] [31] [32] .
FUNCTION OF OX40 ON T CELLS
The importance of OX40-mediated costimulation in the primary, effector, and memory phases of T cell responses has been demonstrated in a variety of model systems in vitro and in vivo [1] . Activation of T cells in the presence of OX40L-expressing cells led to enhanced clonal expansion and secretion of cytokines [11] . Similarly, in vivo, engagement of OX40 on T cells increased expansion, survival and development of T cell memory [33] [34] [35] . Studies using OX40-or OX40L-deficient mice demonstrated impaired T cell responses after immunization with soluble antigen or infectious agents [18, 33, 36, 37] (Table 2) . Studies with OX40-deficient TCR transgenic T cells demonstrated that T cells do not sustain division for long periods after antigen recognition and cannot maintain high levels of anti-apoptotic proteins such as Bcl-2, Bcl-xL, and Bfl-1 resulting in poor long-term survival of effector T cells and memory development [38, 39] . OX40 expression is not dependent on CD28 signals, but several systems have shown that CD28 engagement can augment the cell surface expression of OX40 on T cells, implying that a temporal sequence of events is necessary for optimal T cell proliferation and survival, brought about by sequential engagement of CD28 and OX40 [1] . Collectively, these studies showed that a major role of OX40/OX40L interactions is to regulate the number of effector (protective or pathogenic) T cells that accumulate late in primary responses, and consequently to increase the number of memory T cells that can then respond in secondary immune responses when antigen is reencountered at a later time.
TARGETING OX40-OX40L AXIS IN AUTOIMMUNITY AND TRANSPLANTATION
The expression of OX40 has now been detected on T cells at the site of inflammation in patients and rodents during clinical signs of a wide range of T cell mediated diseases, including experimental autoimmune encephalomyelitis (EAE) [40, 41] , the mouse model of MS, rheumatoid arthritis (RA) [42] [43] [44] [45] , type 1 diabetes [46] , myasthenia gravis [47] , inflammatory bowel disease (IBD) (celiac disease, crohn's disease, ulcerative colitis) [48, 49] , and graft versus host disease (GVHD) [9, 50] (Table 3) . The restricted expression of OX40 on antigen-activated T cells together with the presence of OX40+ lymphocytes and OX40L+ cells at the site of inflammation suggests that targeting OX40 directly or through OX40L may specifically inhibit or dampen pathogenic (including auto-and alloreactive) T cell responses without affecting the remainder of the peripheral T cell repertoire and may therefore be a useful therapeutic strategy for these diseases. Moreover, since strategies directed at OX40+ cells do not target the antigen that is recognized and drives inflammation, they should also allow for clinical intervention without prior knowledge of the disease-relevant peptide. This is particularly important since for many human diseases the antigens recognized by T cells are not well defined. In this section we will provide several examples of how targeting the OX40/OX40L axis with different reagents has been used to dampen T cell mediated immune disorders in experimental animals (for the summary of the data see Table 4 ). 
Experimental Autoimmune Encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) is the best characterized model for the human demyelinating disease that affects the central nervous system (CNS), multiple sclerosis (MS) [51, 52] . The pathology and clinical presentation of EAE is typically characterized by lymphocytic and mononuclear cell infiltration of the CNS, an increase in blood-brain barrier permeability, astrocytic hypertrophy, demyelination, and acute, chronic, or chronic relapsing paralysis [51, 52] . EAE can be induced in a variety of laboratory animal species by immunization with CNS tissue, myelin, or myelin antigens, including myelin basic protein (MBP) and proteolipid protein (PLP), or MBP or PLP derived peptides, given in complete Freund's adjuvant (CFA), or by adoptive transfer of encephalitogenic Th1 cells into naïve, syngeneic animals. Given the instrumental role played by CNS-specific CD4 + T cells in the pathogenesis of MS, and in particular of those cells with a Th1 phenotype, many efforts are presently focused on finding possible ways to suppress this autoimmune response. These include blocking individual cytokines, shifting the phenotype of [54, 55, 57, 59] Type 1 diabetes (NOD) -OX40L
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autoantigen-reactive T cells from Th1 to a Th2 phenotype, inducing T cell tolerance, and inducing regulatory T cells. However, the drawback to these approaches is that many of the current reagents tested in clinical trials, such as IFN-, glatiramer acetate, neutralizing Abs to TNF-, retinoids, (Peroxisome proliferator-activated receptor) PPAR agonists (e.g. thiazolidindiones), and cyclophosphamide, are not specific, and therefore have been found to affect many different cell types and signaling pathways, resulting in undesirable side effects or induction of generalized immune suppression. A more useful and clinically applicable approach would be to target molecules that specifically alter the encephalitogenic potential of autoreactive CD4 + T cells while at the same time minimizing the effects on other cell types and other signaling pathways within T cells.
In EAE models induced by passive transfer of encephalitogenic T cells, de novo expression of OX40 was selectively found on T cells infiltrating the CNS lesions [40, 41] . Similarly, OX40-positive T cells were isolated from the CNS and the draining lymph nodes (DLN) of animals following active immunization with MBP, MOG, or PLP [41, 53, 54] . Clinical signs of EAE correlated with the appearance of OX40-positive T cells, which peaked at disease onset, declined as the disease regressed, and increased during relapses [55] . Similarly, analysis of CNS tissue sections from MS patients revealed that OX40-positive T cells were mainly localized within perivascular inflammatory infiltrates, the tissue parenchyma, and in the vessel lumen of patients with active MS, acute MS, and chronic, active MS lesions [56] . OX40L-positive macrophage-microglia cells were also present within the CNS during EAE, and expression was associated with clinical relapse [55] . In addition, OX40L was prominently expressed on vascular endothelial cells in inflamed spinal cords, suggesting a possible role in T cell transmigration [54] .
Several recent studies have provided strong evidence that targeting OX40 and OX40L in MS patients might be therapeutically beneficial. Initially, Weinberg and colleagues [57] used immunotoxin-fused anti-OX40 antibodies to deplete OX40-positive effector T cells in a rat model of EAE [57] . Administration of the immunotoxin on the same day that encephalitogenic T cells were transferred into naïve recipients, or when the first signs of paralysis were observed, resulted in specific depletion of CNS-infiltrating T cells and prevented any clinical progression of the disease. In a PLPinduced model of EAE, blockade of OX40L with a soluble OX40-immunoglobulin fusion protein (OX40Ig) at disease onset resulted in a marked reduction in clinical signs of EAE [55] . In vitro blockade of OX40L on macrophage-microglia cells isolated from the brains of animals with active EAE also inhibited autoantigen specific T cell proliferation, implying that the OX40 pathway can mediate T cell reactivation within the CNS [55] . In a separate study, treatment with anti-OX40L, before clinical signs of disease, ameliorated EAE in both actively induced and adoptive transfer models [54] . Disease attenuation was associated with reduced T cell and monocytic infiltration into the CNS [54] . Collectively, these studies suggest that OX40:OX40L interactions may be critical for T cell entry into the CNS through the endothelial barriers and their reactivation, proliferation, and accumulation once they have entered the CNS.
Consistent with the idea that OX40:OX40L interactions play a crucial role in the development of EAE is the finding that OX40-and OX40L-deficient mice are much less susceptible to EAE induction, with a strong reduction of pathogenic T cells infiltrating the CNS [56, 58] . Ex vivo studies demonstrated decreased antigen-specific T cell proliferation and diminished IFN-, IL-2, and IL-6 production. Conversely, OX40L-transgenic mice had a greater severity of EAE, despite the delayed disease onset [58] .
Additionally, Chitnis et al. [59] showed that resistance to disease induction in CD28-deficient mice could be overcome with the administration of a second dose of antigen 2 weeks after the initial immunization. Interestingly, anti-OX40L inhibited the development of EAE in these repeatedly immunized CD28-deficient mice. Correlating with this, MBP-reactive T cells that receive OX40 stimulation but not CD28 stimulation are able to mediate encephalitogenicity in a passive transfer model of EAE [60] . Thus, the engagement of OX40 with OX40L can provide sufficient costimulatory signals to promote encephalitogenicity, even in the absence of CD28 costimulation.
Type 1 Diabetes
Type 1 diabetes is believed to be triggered by selective and progressive destruction of the insulin-producing pancreatic -cells by autoreactive T cells [61] [62] [63] . The loss of pancreatic -cells causes insulin deficiency, eventually leading to uncontrolled high blood glucose levels accompanied by severe complications. Current treatments for patients with type 1 diabetes involves a rigorous and invasive regime of testing blood glucose levels many times a day along with subcutaneous injections of recombinant DNA-derived insulin [64] . Another way to restore euglycemia is islet transplantation in diabetic patients. However, the success of this process is largely precluded by potent allograft rejection unless a state of graft-specific T cell unresponsiveness can be induced. Even so, the immunosuppressive regime necessary to protect islets from a recurrent autoimmune response and allorejection may, with time, irreversibly damage kidney function [65] . In this regard, the nature of costimulatory signals that diabetogenic T cells receive during encounters with autoantigen is thought to be one of the decisive factors regulating the progression of diabetes. In non-obese diabetic (NOD) mice, there is strong evidence to suggest that type 1 diabetes can be prevented with considerable ease by targeting CD28:B7 and CD40:CD40L interactions before the onset of diabetes from 2 to 4 weeks of age. However, once the disease process is fully developed, halting type 1 diabetes through these molecules has proved to be extremely difficult [66, 67] . For patients who have developed the first signs of diabetes, the challenging task is to inhibit or suppress the activation of already primed autoreactive T cells, in order to preserve the function of the remaining -cells.
OX40 and OX40L expression have been detected on T cells and CD11b+CD11c+ dendritic cells, respectively, in NOD mice after the onset of insulitis (11-13 weeks), but prior to the complete islet destruction [46] , implying that OX40 and OX40L expression may reflect the result of specific inflammation associated with the disease process. Blocking OX40/OX40L interactions with Ab treatment three times during a one week period had no effect on disease progression at six weeks of age, and only a moderate effect at 9 weeks. However, single treatment at 12 weeks when significant -cell destruction was evident, or continued treatment from week 12 onwards, significantly reduced the incidence of diabetes. Histological examination showed that islet destruction was prevented and insulitis reduced by targeting OX40L. Consistent with this, Martin-Orozco et al. [68] demonstrated that OX40L-deficient mice that were crossed to either NOD background or BDC2.5-transgenic mice did not develop diabetes. These studies show that OX40/OX40L interactions form a late checkpoint in diabetes development.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a serious medical problem, with approximately 1% of the people in the world affected [69] . The disease is characterized by chronic inflammation of the synovial tissue in multiple joints, which leads to joint destruction. Considerable experimental and clinical data suggest that a number of Th1-cell derived cytokines, such as IL-1 and tumour necrosis factor-(TNF-), play a central role in the pathogenesis of RA [70] . Three TNF-blockers, rituximab, etanercept, adalimumab, have been shown to be effective in reducing inflammation and slowing disease progression in patients with RA [71, 72] . However, in some patients there are significant risks associated with the use of these agents, including congestive heart failure, demyelinating diseases, systemic lupus erythematosus, lymphomas, and infections [73] .
In animals undergoing adjuvant-induced arthritis, a marked increase in OX40-positive T cells was first observed at disease onset both in popliteal and inguinal lymph nodes, which remained high throughout the disease [42] . High levels of OX40 expression were also observed on CD4+ T cells purified from synovial fluid of patients with RA [43] [44] [45] 57] . Interestingly, IL-1 [74] and TNF- [75] have both been shown to induce OX40 expression on T cells. Collectively, these data imply that OX40 expression may be a good indicator of immune activation, and possibly of disease activity. Accordingly, in a model of collagen-induced arthritis, administration of anti-OX40L markedly suppressed arthritic symptoms when given at the time when memory T cells were reactivated [44] . More recently, Boot et al. [42] showed that drug delivery to OX40+ T cells using anti-OX40 coated liposomes could affect the course of actively induced arthritis in the adjuvant model. Similarly, Horai et a l . [75] demonstrated that blocking OX40/OX40L interactions with an anti-OX40L antibody before the onset of disease inhibited the development of arthritis in IL-1R -deficient mice. However, the therapeutic effect of anti-OX40L treatment in this model was shown to be limited since once arthritis was induced; anti-OX40L treatment was ineffective. Therefore, in certain patients combinatorial therapy that target both OX40 and TNF or other costimulatory molecules might be potentially additive or synergistic in controlling an ongoing disease.
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) includes a collection of disorders of the gastrointestinal tract that are characterized by intestinal inflammation and a chronic relapsing course associated with local and systemic complications. Traditionally, IBD manifest in different clinical and histological patterns. This includes severe epithelial damage in inflammatory bowel disease (Crohns disease and ulcerative colitis) or villous atropy and crypt hyperplasia (celiac disease), respectively [76] [77] [78] . Although the etiology of these different intestinal diseases are not clear, it has been established that they are caused by breakdown in mucosal tolerance to bacterial flora in the intestine, which results in substantial production of proinflammatory cytokines by resident or infiltrating T cells [77, 79] . It has been shown that transfer of small numbers of CD45RB high CD4+ T cells to immune-deficient (SCID) mice in the absence of regulatory T cells leads to a Th1-mediated colitis that closely resembles IBD seen in humans [80] [81] [82] . In this model, intestinal inflammation was associated with a 15-fold increase in the number of OX40L positive DCs in the mesenteric lymph nodes (MLN). Administration of anti-OX40L at the time of disease induction inhibited T cell proliferation in the MLN as well as their expression of the gut homing integrin 4 7 [83] , and completely prevented the development of colitis. Importantly, delayed treatment (3-weeks after T cell transfer) with anti-OX40L decreased CD4+ T cell infiltration in the colon, suppressed IFN-, TNF, and IL-2 production by lamina propria CD4+ T cells, and significantly improved clinical and histological features of ongoing colitis [84] . Similarly, blockade of OX40/OX40L interactions with OX40-Ig fusion protein ameliorated ongoing IBD in several other mouse models, including hapten-induced colitis [85] , dextran sulphate-induced colitis [86] , and spontaneous development of colitis in IL-2 knockout mice [85] . Interestingly, in the CD4+CD45RB high -transfer model of colitis, blocking OX40/OX40L interactions was shown to be more effective at preventing clinical signs of disease than TNF-specific antibodies [84] , although a combination of antibodies to both OX40L and TNF was most effective. These results together with clinical studies showing that the majority of biopsy specimens of patients with various forms of IBDs are enriched with OX40+ and OX40L+ cells [48, 49] suggesting that targeting these receptor/ligand pair alone or in combination with other molecules such as TNF-may be a promising new strategy to treat ongoing T cell reactions in the gut.
Graft-Versus-Host Disease
Graft-versus-host disease (GVHD) is a major and potentially lethal complication of allogeneic bone marrow transplantation (BMT) [87, 88] . It is initiated by donorderived alloreactive CTLs and CD4+ T lymphocytes, it is then amplified by elaboration of cytokines [89, 90] . Studies in animal models have indicated enhanced OX40 expression by lymphocytes in the blood as early as 5 days post-BMT and peaking at 12 days [91] . As the increase in OX40 expression occurred in parallel with the GVHD, it has been proposed that OX40 expression may be a useful marker for predicting GVHD or for monitoring immune responses to the graft. In this regard, clinical data in partially mismatched human bone marrow transplants indicates that OX40 expression, while not predictive of acute GVHD (aGVHD) [50, 92, 93] , may be predictive of chronic GVHD (cGVHD) [9, 50] and closely correlated with the resistance to anti-GVHD immunosuppressive therapy [9, 92] .
Using an acute non-irradiated semi-allogeneic GVH system in mice, Stuber et al. [94] demonstrated that blocking OX40/OX40L interactions with an OX40-Ig fusion protein, on the same day as GVHD was induced completely prevented the intestinal manifestations of aGVHD. Later, Tsukada et al. [95] extended these studies into lethally irradiated murine F1 recipients of parental donor grafts by showing that administration of anti-OX40L significantly reduced the lethality of aGVHD and other manifestations of the disease, such as loss of body weight, hunched posture, diarrhea, and patchy alopecia. The majority (70%) of mice treated with the antibody survived up to 80 days after BMT, whereas all mice treated with control antibodies died within 43 days. Blazer et al. [96] showed that blocking OX40/OX40L interactions with anti-OX40L resulted in less severe GVHD, and conversely, that administration of an anti-OX40 agonistic antibody promoted disease. Notably, despite the fact that OX40 was up-regulated on both CD4 and CD8 T cells isolated during GVHD, the major effects of blocking OX40 signals were on CD4 and not CD8 T cell alloresponses. These results together with others [97, 98] suggest that reagents that are designed to block OX40/OX40L interactions could be promising therapy for human GVHD and possibly for some solid organ transplantations such as heart allograft.
Studies of blocking CD28 and CD154 (CD40L) have repeatedly demonstrated that targeting these pathways can only prolong the survival of 'tolerogenic' grafts (such as heart and kidney) but not 'immunogenic' grafts (such as skin) [99] [100] [101] , implying that under more stringent conditions alternative pathways or molecules can compensate for the lack of CD28 and/or CD40L. In this regard, using CD28/CD154 double-knockout mice, Demirci et al. [102] demonstrated that OX40 signals are critically involved in CD28/CD154-independent skin allograft rejection. Accordingly, blocking OX40/OX40L pathway, but not other costimulatory molecules belonging to the Ig superfamily (ICOS/ICOSL), or TNFR-superfamily 4-1BB/4-1BBL, or CD27/CD70, prolonged skin allograft survival in CD28/CD154 double-knockout mice. In contrast to the GVHD models described above, blocking OX40/OX40L markedly inhibited both CD4 and CD8 T cell mediated skin allograft rejection [101, 102] . Interestingly, when similar experiments were carried out in wild-type (C57BL/6) mice, administration of mCTLA-4Ig, anti-CD154, or anti-OX40L alone failed to inhibit skin allograft rejection, but the combination of all three antibodies promoted long-term allograft survival. Collectively, these results suggest that while blocking OX40/OX40L interactions may prevent allograft rejection in some patients such as those with GVHD, it may be necessary to target multiple costimulatory pathways to prevent more stringent allograft rejection.
TARGETING THE OX40-OX40L AXIS IN ALLERGY AND ASTHMA
Asthma is a chronic inflammatory disorder of the airways that is caused by an immune response to airborne allergens, and results in massive infiltration of the bronchial mucosa by lymphocytes and eosinophils. This is accompanied by goblet cell hyperplasia and mucus production within the bronchioles, with the overall result being impeded airflow and airway hyper-reactivity (AHR) [103, 104] .
Evidence from asthmatic patients and from animal models of this disease indicate that memory Th2 cells secreting the cytokines IL-4, IL-5, IL-9, and IL-13 are the major driving force behind allergic asthma and these CD4 cells are thought in many cases to arise early in life [103] . Considering their pivotal role in regulating lung inflammation, Th2 cytokines are obvious targets for dampening asthmatic symptoms and inhibitory reagents to these molecules or their receptors are currently being evaluated. However, it is unlikely that such a strategy will affect the ability of memory Th2 cells to persist or to continue to make cytokines, and therefore any benefit may be short-lived. An alternative strategy that has the potential to offer more long-term benefits is to target molecules that may control the survival or reactivity of memory Th2 cells.
Initial studies in animal models of asthma did reveal that B7/CD28 interactions are critical for the priming of allergenspecific Th2 cells and for Th2 recall responses in situations where antigen rechallenge was less than three weeks after initial priming [105] [106] [107] [108] [109] [110] . However, more recent data from several other groups indicated that inhibiting these interactions was not effective when antigen rechallenge was three or more weeks after priming, suggesting that CD28 blockade may have a limited value in treatment of established disease [109] . In addition to its important role in many Th1-mediated immune responses, there is now considerable in vitro and in vivo data in both murine and human systems to suggest that OX40/OX40L interactions may be also important in promoting the development of Th2 cells [111] [112] [113] [114] [115] [116] [117] . Consistent with these studies, in a well established murine model of asthma it was shown that exposure of sensitized animals to antigen via the airways causes a strong and rapid upregulation of OX40 expression on the surface of memory Th2 cells, and OX40L on CD11b+CD11c+ DCs, both in the lungs and in secondary lymphoid organs, implying that OX40/OX40L interactions may be important for the initiation and/or amplification of allergic responses [12] ( and unpublished observations SSA and MC). In support of this, using OX40-deficient mice Jember et al. [118] demonstrated a requirement for OX40 signals in the initial development of asthmatic symptoms, a finding that was subsequently reproduced in OX40L knockout mice [119] . However, as OX40 is essential for primary T cell responses, these studies did not reveal whether OX40 regulates memory Th2 cells or whether OX40/OX40L interactions may represent clinically relevant targets for preventing late phase recall immune responses in asthmatic patients. To test these possibilities, anti-OX40L was administered to sensitized mice at the time of re-challenge with aerosolized antigen [12] . Specific blockade of OX40-OX40L interactions (several months after sensitization) reduced the accumulation of CD4+/CD44 high OX40+ cells in the lung and draining LNs, and almost completely suppressed pulmonary inflammation, mucus production, goblet-cell hyperplasia, allergen specificIgE production, and the development of AHR. Consistent with these studies, naïve mice receiving OX40-deficient TCR-transgenic memory Th2 cells showed little or no increase in the numbers of inflammatory cells recovered from bronchial lavages, relatively normal lung histology, and a virtual absence of Th2 cytokines. Additional mechanistic studies indicated that OX40 signals regulated the number of memory/effector Th2 cells that were generated after they reencountered antigen in the lung and lung draining lymph nodes. These results suggest that targeting OX40-OX40L interactions may be useful therapeutically for the modulation of ongoing chronic inflammation in allergic disorders and for preventing the persistence of asthmatic-like reactions. This approach has a distinct advantage of blocking the production of several Th2 cytokines simultaneously rather than suppressing the activity of a single cytokine, and may profoundly affect the ability of memory cells to continue to mount a Th2 response.
TARGETING THE OX40-OX40L AXIS IN VIRAL INFECTIONS
Insight into the role that OX40 plays in immunity to viral infections has been primarily acquired using gene-deficient mice. In accordance with protein immunization studies [33] , OX40 -/-mice had defective CD4 + T cell responses following infection with either influenza or lymphocytic choriomeningitis virus (LCMV) [37] . Despite impaired T cell help, cytotoxic T cell and antibody responses were comparable to wild type levels. Furthermore, humoral responses elicited by either Vesicular Stomatitis Virus (VSV) [37] or Theiler's murine encephalomyelitis virus [120] , were also unaltered in OX40 -/-mice. Similar results were observed following inhibition of OX40-OX40L interactions with OX40:Ig fusion protein during influenza infection, although in this situation both CD4 + and CD8 + pulmonary T cell numbers were reduced [121] . Critically, in all these systems, control of viral replication was not affected by the inhibition or absence of OX40 signaling. These data suggest that OX40 plays no role in protective immunity to acute viral infections. However, OX40 and OX40L expression in these models was not well characterized. In the case of the pulmonary fungal infection with Cryptococcus neoformans, which induced only low levels of OX40L expression in the lung, stimulation of T cells with OX40L:Ig fusion protein actually promoted fungal clearance [122] . It is therefore conceivable that enhanced OX40 signaling over and above the level naturally occurring in vivo could accelerate clearance of a given virus. This might be particularly relevant in the case of persistent and latent infections where natural levels of protection are not sufficient for expulsion of the pathogen. Information regarding the expression of OX40 and its ligand during acute and persistent/latent human viral infections is limited however, and represents an important area for future clinical research.
Given its role in T cell memory development, OX40 augmentation also has the potential to enhance levels of long-term protection afforded by vaccinations. Coadministration of an agonistic anti-OX40 antibody with SIV gp130 in rhesus monkeys has been reported to enhance virus-specific T cell and antibody recall responses, suggesting that using OX40 stimulation as an adjuvant could improve the efficacy of HIV vaccination strategies [123] . These results raise the possibility that triggering OX40 could booster vaccination efficacy against other viral (and non viral) pathogens. Indeed, stimulation of OX40, in cooperation with 4-1BB, during vaccination with an OVAexpressing poxvirus vector enhanced OVA-specific memory responses [124] . Furthermore, recombinant poxvirus expressing OX40L in combination with B7-1, ICAM-1 and LFA-3 also promoted CD4 + and CD8 + T cell memory development [125] . Taken together, these data highlight the potentially exciting approach of utilizing recombinant viral vectors expressing the vaccinating antigen of choice in combination with costimulatory ligands. If successful, a replicating OX40L-expressing viral vector would not only be extremely immunogenic, but also bypass the requirement for expensive monoclonal antibodies or fusion proteins required to stimulate OX40, representing a cheaper and more effective alternative to many current vaccines.
Although the immune system is critical for protection from infection, exuberant responses induced by certain viruses are not only surplus to requirement, but can actually be harmful. This is particularly relevant in the lung where inflammation in response to infection can result in airway occlusion and clinical disease. Illness induced by pulmonary influenza infection is associated with T cell inflammation and pro-inflammatory cytokine production [126] [127] [128] . Following inhibition of OX40-OX40L interactions with an OX40:Ig fusion protein, influenza-induced T cell inflammation and associated weight loss and cachexia were reduced, even when treatment was initiated after the onset of disease [121] . Importantly, unlike inhibition of CD28 signaling [129] , OX40:Ig did not alter immune control of influenza replication, implying that OX40 inhibition strikes a fine balance between protective immunity and pulmonary inflammation. The observation that memory T cell recall responses to influenza re-infection were unaffected by OX40:Ig further suggests that this anti-inflammatory approach may be applicable to a variety of viral infections where infection-induced immunopathology is a causative factor in clinical disease.
Viral Hijacking of OX40
The majority of research to date has focused on the role that OX40 plays in global immune responses to viral infections. However, more intimate interactions between OX40 and viruses are being uncovered. Recently, OX40 was identified as the primary receptor for feline immunodeficiency virus (FIV) [130, 131] . By using OX40 as its receptor, FIV preferentially binds to and infects activated CD4 + T cells, a parallel also observed in HIV infection [132] . By replicating in and subsequently killing these cells, FIV preferentially depletes virus-specific T cells that would otherwise mediate antiviral immune responses. T cell tropic viruses may also exploit the OX40-OX40L axis to aid their dissemination. Human T cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T cell leukemia (ATL). Following infection, HTLV-1 induces OX40 expression in a co-operative process involving NF B and the viral oncoprotein, Tax [133] . Interestingly, leukemic cells isolated from some ATL patients displayed OX40 dependent adhesion to endothelial cells [27] , suggesting that virusinduced OX40 expression enhances leukemic cell infiltration. Importantly, due to the persistent/latent nature of HTLV-1 infection, this increased capacity of leukemic cell migration may also enhance dissemination of virus within the host.
Given their intracellular lifecycle, it is conceivable that viruses may also use OX40-induced intracellular signals to their advantage. The continual battle between viruses and pro-apoptotic members of the TNF receptor superfamily has been the topic of much research and is reviewed elsewhere [134] . The anti-apoptotic signal delivered by OX40 represents a potential weapon for viruses in this struggle for survival. Indeed, OX40 stimulation of leukemic cells isolated from ATL patients rendered them resistant to Fasmediated apoptosis, suggesting that HTLV-1 induced OX40 expression promoted the survival of infected cells [135] . Furthermore, viruses can hijack transcriptional activation events triggered by OX40 to induce the expression of their own genes. A number of viruses including cytomegalovirus [136, 137] and HIV [138] have NF B response elements incorporated into their genomes. In the case of CMV these NF B binding elements are not required for lytic replication [139] although they may play a role in viral reactivation from latency, but for HIV it has been shown that OX40-induced NF B activation enhanced productive viral replication [140] . T lymphocytes are the host cells of choice for the replication and latency of a number of human viruses, and the possible influence that OX40 has on the replication, survival and/or reactivation from latency of these pathogens represents an interesting area for future research.
OX40 therefore has a number of divergent and sometimes paradoxical roles in viral infections. Although it is a promising target for enhancing protection from infection and reducing viral-induced immunopathology, the positive effect OX40 may have on virus replication and survival in T cells raises new considerations for its manipulation, making the infectious status of the patient of paramount importance. The expression and function of OX40 in human viral infections is clearly an area requiring investigation. Not only will such research aid the evaluation of the safety of OX40 augmentation in the clinic, it may also provide the key to identifying novel anti-viral strategies in the future.
TARGETING THE OX40-OX40L AXIS IN CANCER
The immune system is geared towards recognizing and clearing infectious agents invading the body, but conversely is set up to ignore self-proteins, and hence cannot efficiently attack cancerous cells. T cells either ignore the tumor, or become tolerized when encountering tumor cells in the absence of inflammation.
In this regard, costimulatory molecules, such as CD28, have been used to provide essential signals to T cells, mimicking inflammation and allowing the generation of tumor specific responses. Experiments carried out in Allison and Chen's laboratories in the early 1990s demonstrated that conferring B7-1 expression to murine transplantable tumors was sufficient to induce potent CD8 T cell responses [141] and promote regression of immunogenic tumors [142] . However, this therapeutic strategy was found to be ineffective in poorly immunogenic tumors, even in combination with co-expression of immunostimulatory cytokines [143] [144] [145] . The limitation of these approaches may result from the cross-reactivity of B7.1 with CTLA-4, which delivers an inhibitory signal to T cells, thus attenuating a T cell response [146] .
For poorly immunogenic tumors, while it seems critical to provide signals to provoke initial anti-tumor responses, additional signals might be required to sustain the response. Some experimental tumor models have shown that tumor cells can themselves upregulate B7-1 and B7-2, thus evoking a T cell response. However, despite the initial presence of tumor reactive T cells, tumors are not completely rejected and re-grow, and the immune response falters. Similarly, adoptive immunotherapy with in vitro activated CD8 T cells has demonstrated a correlation of tumor regression with the persistence of tumor-reactive T cells [147] [148] [149] . This suggests that the biggest hurdle in cancer therapy is not to generate tumor specific T cells, but rather to sustain them over time.
OX40 expression was found in one third of tumorinfiltrating cells and in the draining LN of human melanoma and head and neck carcinomas [150] (Table 5) . OX40+ T cells were also found in approximately one fifth of primary colon cancers, which correlated with survival [151] . One study characterized the expression of OX40 and CD25 in primary cutaneous melanoma samples of patients, demonstrating the association of the CD25+OX40+ lymphocytic infiltrates with decreased tumor sizes as well as the lower frequency of distant visceral metastases [152] . OX40 expression has also been detected on T cells within malignant lymphomas [153] (Table 5) . These findings are then consistent with the idea that OX40+ T cells represent tumor reactive T cells. In line with this, co-culture of autologous CD4 T cells isolated from a melanoma, with an MHC class II+ melanoma cell line transfected with OX40L, resulted in T cell proliferation and in vitro tumor regression [150] .
Although OX40+ T cells may be found in or around tumors, the majority of tumors or professional APC within tumors do not express OX40L [154] , implying that signals from OX40 might not naturally be delivered. This idea has now been examined in many experimental tumor models ( Table 6 ). Recombinant adenovirus transduction of OX40L in tumor cells was shown to stimulate tumor specific cytotoxic T cells, and induced significant tumor suppression and a survival advantage [155, 156] . Likewise, administration of soluble OX40L or OX40 agonist antibody enhanced anti-tumor responses [8, [157] [158] [159] [160] , inhibited brain, liver or lung metastases [158, 160, 161] , and led to tumor free survival in mouse models of melanoma, sarcoma, colon cancer, breast cancer, thymoma and glioma.
The efficacy of OX40 ligation was markedly augmented when combined with cytokine therapies and/or engagement of other costimulatory molecules ( Table 6) . GM-CSF is a potent factor to activate APCs, thus able to increase antitumor responses when used together with OX40, a T cell stimulator. Vaccination with OX40L to inhibit colon and breast carcinomas was significantly enhanced by combination therapy with intra-tumoral injection of a herpes simplex virus vector encoding GM-CSF [158] . Another group also demonstrated that colon carcinoma cells transduced with OX40L together with GM-CSF were highly suppressed to grow in the hosts compared to tumor cells transfected with OX40L alone. Moreover, subcutaneous vaccination with irradiated GM-CSF/OX40L transduced tumor cells eradicated lung metastases more efficiently than did vaccination with cells transfected with GM-CSF or OX40L alone [162] . Combination therapy with other molecules might also promote the tumor inhibitory effect. Molecular transfer of OX40L and CD40L on B-Chronic Lymphocytic Leukemia (B-CLL) cells was shown to synergistically stimulate greater responses of tumor-reactive CD8 T cells in vitro [163] . Also, adenovirus-mediated delivery of IL-12 with agonist antibodies to 4-1BB and OX40 induced drastically higher tumor specific CTL activity with increased memory CTL responses against parental carcinoma cells than any single treatment or double treatment in this model [161] . In addition, treatment with OX40 agonist antibody increased efficacy of adoptive immunotherapy of pulmonary metastases and intracranial tumors when combined with activated tumor-draining lymph node T cells [164] .
While engagement of OX40 efficiently has been shown to result in CTL activity against tumors, in most of the cases, the effect requires the presence of CD4 T cells [155, 158, 161, 164] . OX40-based therapy induces potent tumor specific CD4 memory T cells that can transfer protection to naïve mice [159] , suggesting that OX40 might preferentially target tumor-reactive CD4 T cells, which then provide increased help to positively influence the function and survival of CD8 T cells [154] . However, recent data have shown that OX40 can also directly stimulate CD8 T cells. Administration of an anti-OX40 agonist antibody enhanced CD8 T cell responses against a thymoma in MHC class II knockout mice [8] . Furthermore, in the absence of OX40 signals, CD8 T cells failed to persist over time and suppress thymoma growth in an adoptive immunotherapy setting [165] . This indicates that OX40 signals provided during T cell priming can program the survival capabilities of T cells, and thus dictate the longevity of anti-tumor responses. One last feature of OX40 signaling is the capability to affect immunological tolerance. Agonist antibodies to OX40 were shown to not only prevent the induction of tolerance, but also reverse tolerance in an experimental setting [166] . This unique characteristic of OX40 costimulation makes it particularly appealing in tumor immunity, where reversal of the tolerizing effects from tumor cells can dramatically augment the anti-tumor response, leading to complete eradication.
CONCLUSIONS AND FUTURE DIRECTIONS
The discovery of T cell costimulatory pathways and the development of reagents to enhance or block these pathways have provided novel strategies to treat immunological disorders. There is now a considerable body of literature that shows that OX40 costimulation regulates T cell expansion [191, 192, 193] Angiocentric lymphoma 4/4-100% + N.D. [191, 192] Large cell lymphoma 10/21-48% + N.D. [191, 192] Lymphoma with histiocytic component 6/7-86% + N.D. [191, 192] Hodgkin's lymphoma 7/20-RS cells + N.D. [191, 192] [27, 194, 195] Primary colon cancers Lymphocytes + N.D. [151] Primary breast tumors lymphocytes + N.D. [159, 196] Mycosis fungoides 3/8-+ N.D. [195] Cutaneous melanoma CD4 T cells CD8 T cells + + N.D. N.D. [152] Lymphomatoid papulosis /42-38% + N.D. [197] PTLC: peripheral T cell lymphoma; ALCL: anaplastic large cell lymphoma; AIL: angioimmunoblastic lymphoma; ATLL: adult T cell leukemia. N.D.: not determined.
and cell division and is critical for long-term survival. This not only impacts the magnitude of the primary response and its efficiency, but also directly affects the number of T cells that can go on to form the memory pool. These properties together with the restricted expression of OX40 on antigenactivated T cells make it an ideal therapeutic target for specific immune intervention. Indeed, many studies in experimental disease models have now shown that inhibiting this interaction after the onset of clinical symptoms can be useful therapeutically in autoimmunity, organ transplantation, and asthma. Conversely, reagents that augment OX40 signals have now shown therapeutic efficacy in models of tolerance, cancer and infectious disease. However, although many of these preventative and therapeutic approaches have been extremely promising, to date they have been tested only in small-animal models. In the coming years the potential of these reagents to improve treatment of patients is going to be determined only by rigorous clinical trials, and we eagerly await their findings.
Experience from past clinical trials have shown that for therapy of human disease, it is unlikely that one target will be sufficient to inhibit or enhance complex biological processes that have superimposed phases of acute and chronic inflammation. Therefore, the use of combination therapy targeting different stages of a particular disease also needs to be investigated further. This approach may circumvent the sometimes limited therapeutic window for use of anti-OX40 as a single therapeutic agent. In this regard, the most encouraging studies to date have used combinatorial approaches. Studies combining modulation of OX40 signals with approaches designed to enhance APC function (GM-CSF expressing vaccines or anti-CD40) show promise for treating poorly immunogenic tumors in murine models. Similarly, blocking multiple costimulatory pathways (OX40, CD28, and CD40) have proved more useful at inhibiting highly immunogenic skin allografts and may be required for complete prevention of autoimmunity. Tumor bearing mice immunized with TRP-2/OX40L mRNA-co-transfected DCs CD4 [198] Melanoma (B16)
Lung carcinoma
Colon carcinoma (C26)
Adenovirus-vector-mediated gene transfer of OX40L to tumor cells CD4 and CD8 [155] T cell lymphoma (EL4)
Tumor transfection with OX40L CD4 and CD8 [156] A20 lymphoma
Tumor cells secreting IL-12 and OX40 mAb CD4 [199] Colon carcinoma (C26)
Tumor transfection with OX40L/GM-CSF/CD40 CD4 and CD8 [162] Colon carcinoma OX40 mAb CD4 [161] Colon carcinoma
Tumor transfection with OX40L CD4 and CD8 [162] Hepatic colon metastases IL-12 + 4-1BB mAb + OX40 mAb CD4 [161] Breast cancer (SM1 and 4T1)
-OX40L:Ig CD4 [157] Sarcoma, melanoma -OX40L:Ig; OX40 mAb CD4 [159] Sarcoma, glioma OX40 mAb CD4 and CD8 [160] BM-185 pre-B cell lymphoma
Tumor transfection with CD80 and OX40 mAb CD8 [200] Human B-chronic lymphocytic leukemia Molecular transfer of CD40 and OX40L to B-CLL cells CD4 and CD8 [163] MCA 205 pulmonary metastasis, intracranial tumors OX40 mAb CD4 and CD8 [164] Acute myeloid leukemia Retroviral transfection of leukemia DCs with OX40L CD4 [201] Lung metastasis
Breast carcinoma (4T1) -OX40L:Ig CD4 and CD8 [158] Established murine sarcoma 4-1BB mAb + OX40 mAb CD8 [202] Thymoma OX40 mAb CD8 [8] MCA: 3-methylcholanthrene 205.
